JP2024540483A5 - - Google Patents
Info
- Publication number
- JP2024540483A5 JP2024540483A5 JP2024529341A JP2024529341A JP2024540483A5 JP 2024540483 A5 JP2024540483 A5 JP 2024540483A5 JP 2024529341 A JP2024529341 A JP 2024529341A JP 2024529341 A JP2024529341 A JP 2024529341A JP 2024540483 A5 JP2024540483 A5 JP 2024540483A5
- Authority
- JP
- Japan
- Prior art keywords
- cancer
- optionally substituted
- alkyl
- halo
- independently selected
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163281508P | 2021-11-19 | 2021-11-19 | |
| US63/281,508 | 2021-11-19 | ||
| PCT/US2022/080165 WO2023092088A1 (en) | 2021-11-19 | 2022-11-18 | Cdk2 inhibitors and methods of making and using same |
| USPCT/US2022/080165 | 2022-11-18 | ||
| PCT/US2022/080199 WO2023092107A1 (en) | 2021-11-19 | 2022-11-19 | Cdk2 inhibitors and methods of making and using same |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024540483A JP2024540483A (ja) | 2024-10-31 |
| JP2024540483A5 true JP2024540483A5 (enExample) | 2025-11-27 |
Family
ID=84901264
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024529341A Pending JP2024540483A (ja) | 2021-11-19 | 2022-11-19 | Ｃｄｋ２阻害剤及びその製造方法及び使用方法 |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US20250074895A1 (enExample) |
| EP (1) | EP4433470A1 (enExample) |
| JP (1) | JP2024540483A (enExample) |
| CN (1) | CN118265706A (enExample) |
| WO (2) | WO2023092088A1 (enExample) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20240020735A (ko) | 2021-05-07 | 2024-02-15 | 카이메라 쎄라퓨틱스 인코포레이티드 | Cdk2 분해제 및 그 용도 |
| US11932648B2 (en) | 2021-06-28 | 2024-03-19 | Blueprint Medicines Corporation | CDK2 inhibitors |
| CN119072471A (zh) * | 2022-04-28 | 2024-12-03 | 正大天晴药业集团股份有限公司 | 一种吡唑取代环戊酯衍生物及其用途 |
| CN120239698A (zh) * | 2022-11-17 | 2025-07-01 | 山东绿叶制药有限公司 | Cdk2抑制剂及其制备方法和应用 |
| WO2024178335A2 (en) * | 2023-02-23 | 2024-08-29 | Accutar Biotechnology, Inc. | Novel macrocyclic aminopyrazole compounds as cdk2 inhibitors |
| WO2025062334A1 (en) * | 2023-09-20 | 2025-03-27 | Beigene Switzerland Gmbh | 4-((5-(3-(4-(pyridin-2-yl)cyclopentyl)-1 h-pyrazol-3-yl)amino)-benzenesulfonamide derivatives and similar compounds as cdk inhibitors for the treatment of cancer |
| WO2026024674A1 (en) | 2024-07-22 | 2026-01-29 | Genesis Therapeutics, Inc. | Methods of treating skp2-associated cancers |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ523656A (en) * | 2000-08-31 | 2004-11-26 | Pfizer Prod Inc | Pyrazole derivatives and their use as protein kinase inhibitors |
| WO2020050653A1 (ko) | 2018-09-05 | 2020-03-12 | 삼성전자 주식회사 | 이동 통신 시스템에서 papr 감소를 위한 기준 신호 시퀀스 생성 방법 및 장치 |
| IL284589B2 (en) * | 2019-01-31 | 2025-10-01 | Pfizer | 3–Carbonylamino–5–cyclopentyl–h1–pyrazole compounds with cdk2 inhibitory activity |
-
2022
- 2022-11-18 WO PCT/US2022/080165 patent/WO2023092088A1/en not_active Ceased
- 2022-11-19 WO PCT/US2022/080199 patent/WO2023092107A1/en not_active Ceased
- 2022-11-19 US US18/710,715 patent/US20250074895A1/en active Pending
- 2022-11-19 EP EP22840847.2A patent/EP4433470A1/en active Pending
- 2022-11-19 CN CN202280076541.5A patent/CN118265706A/zh active Pending
- 2022-11-19 JP JP2024529341A patent/JP2024540483A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2024540483A5 (enExample) | ||
| JP2024524373A5 (enExample) | ||
| JP2024522766A5 (enExample) | ||
| JP2023520333A5 (enExample) | ||
| US9284298B2 (en) | Pyrazolyl-pyrimidine derivatives as kinase inhibitors | |
| US8426430B2 (en) | Quinazoline derivatives | |
| JP2021519783A5 (enExample) | ||
| KR101668931B1 (ko) | 항종양제의 효과 증강제 | |
| JP2022526266A5 (enExample) | ||
| US11084811B2 (en) | Compounds for treatment of cancer | |
| JP2009526009A (ja) | Ｃｄｋ阻害剤、および成長因子抗体または抗有糸分裂剤を含む組合せ | |
| CN111601797A (zh) | 苯并哌啶或杂芳基并哌啶类衍生物、其制备方法及其在医药上的应用 | |
| US8440675B2 (en) | Potentiator of radiation therapy | |
| US20170015672A1 (en) | Substituted pyrrolo[2,3-d]pyrimidines for selectively targeting tumor cells with fr-alpha and fr-beta type receptors | |
| JP2022501436A5 (enExample) | ||
| CN116323590A (zh) | 取代苯并或吡啶并嘧啶胺类抑制剂及其制备方法和应用 | |
| JP2013530130A (ja) | ヘテロアリール（アルキル）ジチオカルバメート化合物、その調製方法及び使用 | |
| JP2024543207A5 (enExample) | ||
| JP2008521826A (ja) | エポチロンおよびタンパク質チロシンキナーゼ阻害剤を含む組合せ剤およびその医薬的使用 | |
| TWI638825B (zh) | 抑制癌症及病毒之化合物 | |
| JP2023535790A5 (enExample) | ||
| JP2021514399A5 (enExample) | ||
| JP2024515061A5 (enExample) | ||
| EP4244222B1 (en) | Succinate and crystal form thereof as therapeutics | |
| JP2022502378A5 (enExample) |